HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen

Materials & methods: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospective case series of HER2 positive esophageal...

Full description

Bibliographic Details
Main Authors: Scott A Wu, Dan Tong Jia, Margaret Schwartz, Mary Mulcahy, Kuanghua Guo, Matthew C Tate, Sean Sachdev, Nicolas Kostelecky, David J Escobar, Daniel J Brat, Amy B Heimberger, Rimas V Lukas
Format: Article
Language:English
Published: Taylor & Francis Group 2023-09-01
Series:CNS Oncology
Subjects:
circulating tumor cells
esophageal cancer
HER2
intrathecal
leptomeningeal metastases
trastuzumab
Online Access:https://www.futuremedicine.com/doi/10.2217/cns-2022-0018

Internet

https://www.futuremedicine.com/doi/10.2217/cns-2022-0018

Similar Items